Jian Guan, MD
Hematology & Oncology · Houston, TXNPI 1053799304
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,205 of the $2,688 with a category attached, or 82.0%. It is spread thinly across 36 manufacturers, the largest accounting for just 18.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $685, 4.1 times the $168 reported in 2019. That places this record below the midpoint for hematology & oncology clinicians in TX, where the typical reported total is $3,204.
Across 81 payments — averaging $33.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$493
- Takeda Pharmaceuticals U.S.A., Inc.$290
- Johnson & Johnson$200
- Astellas Pharma US Inc$197
- Novartis$148
- AstraZeneca$142
- plus $1K from 30 others
Across 11 payments — averaging $805.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bayer$9K
What the payments were for
- Food & beverage$2,20582%
- Education$48318%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 10 | $493 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $290 |
| Johnson & Johnson(3 entities) | 6 | $200 |
| Astellas Pharma US Inc | 7 | $197 |
| Novartis | 7 | $148 |
| AstraZeneca | 3 | $142 |
| Intercept Pharmaceuticals, Inc. | 1 | $121 |
| Amgen | 2 | $110 |
| Rigel Pharmaceuticals, Inc. | 2 | $84 |
| Pfizer | 3 | $69 |
| Sanofi | 2 | $69 |
| Ipsen Biopharmaceuticals, Inc | 2 | $63 |
| Daiichi Sankyo Inc. | 2 | $55 |
| Octapharma USA, Inc. | 1 | $54 |
| Incyte Corporation | 2 | $50 |
| GSK | 2 | $49 |
| Tempus AI, Inc | 2 | $47 |
| Bristol Myers Squibb | 2 | $47 |
| Bayer | 1 | $33 |
| Merck | 1 | $28 |
| Regeneron Healthcare Solutions, Inc. | 1 | $28 |
| Pharmacosmos Therapeutics Inc. | 1 | $27 |
| Array Biopharma Inc | 1 | $27 |
| Melinta Therapeutics, LLC | 1 | $26 |
| Sobi, Inc | 1 | $24 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $24 |
| E.r. Squibb & Sons, L.L.C. | 1 | $24 |
| Taiho Oncology, Inc. | 1 | $23 |
| Beone Medicines USA, Inc. | 1 | $20 |
| BTG International Inc. | 1 | $20 |
| Genmab U.S., Inc. | 1 | $19 |
| Pharmaessentia USA Corporation | 1 | $18 |
| Tolmar, Inc. | 1 | $15 |
| Pharmaand GmbH | 1 | $15 |
| Nevro Corp. | 1 | $14 |
| Puma Biotechnology, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RETEVMO$103
How this compares
$2,688 in reported general payments places this provider in the 45th percentile of 838 hematology & oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ondansetron OdtOndansetron | 19 | $333 |
| Prochlorperazine Maleate | 18 | $222 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Houston
- Devesh PandyaHouston$1.8M
- Elias JabbourHouston$1.3M
- Naval DaverHouston$853K
- Jorge Cortes-FrancoHouston$627K
- Courtney DinardoHouston$478K
- Prithviraj BoseHouston$463K
- Milind JavleHouston$326K
- Loretta NastoupilHouston$309K
- Boyu HuHouston$281K
- Luis CamachoHouston$276K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.